Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 6/20 | 0.66 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 5/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16348121 | 0.81 | OPRM1 (0.56) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL13234380 | 0.81 | OPRM1 (0.56) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL13214097 | 0.81 | OPRM1 (0.56) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL24435763 | 0.81 | OPRM1 (0.56) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL13234168 | 0.80 | OPRM1 (1.00) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL16348130 | 0.80 | OPRM1 (1.00) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL15139295 | 0.80 | OPRM1 (1.00) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL13214086 | 0.80 | OPRM1 (1.00) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL31545197 | 0.80 | OPRM1 (1.00) | OPRM1ACE2CNR2CNR1 | |
| SCHEMBL31103513 | 0.80 | OPRM1 (1.00) | OPRM1ACE2CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11344527-B2 | Methods and compositions for treating cancer | SUTTER BAY HOSPITALS (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344527-B2 | Methods and compositions for treating cancer | CNR2, CNR1, JUP | OPRM1 525/4885ACE2 4355/4885CNR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.